We are live on ! Find out more
OLMA icon

Olema Pharmaceuticals

76 hedge funds and large institutions have $1.01B invested in Olema Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 28 increasing their positions, 15 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 9

87% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 15

10% more funds holding

Funds holding: 6976 (+7)

0% more funds holding in top 10

Funds holding in top 10: 55 (0)

0.3% less ownership

Funds ownership: 93.17%92.88% (-0.3%)

3% less capital invested

Capital invested by funds: $1.05B → $1.01B (-$34.6M)

Holders
76
Holders Change
+7
Holders Change %
+10.14%
% of All Funds
1.33%
Holding in Top 10
5
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.09%
New
17
Increased
28
Reduced
15
Closed
9
Calls
$546K
Puts
Net Calls
+$546K
Net Calls Change
+$546K
Name Holding Trade Value Shares
Change
Change in
Stake
Ameriprise
26
Ameriprise
Minnesota
$5.82M -$8.4M -311,148 -60%
Charles Schwab
27
Charles Schwab
California
$5.4M +$3.09M +114,590 +141%
Goldman Sachs
28
Goldman Sachs
New York
$4.15M +$2.74M +101,507 +207%
ACP
29
Acuta Capital Partners
California
$4.15M +$4.06M +150,500 New
PAMS
30
Pictet Asset Management (Switzerland)
Switzerland
$4.14M +$4.05M +150,133 New
Russell Investments Group
31
Russell Investments Group
United Kingdom
$3.46M +$3.38M +125,383 New
Deutsche Bank
32
Deutsche Bank
Germany
$2.93M +$191K +7,094 +7%
Two Sigma Investments
33
Two Sigma Investments
New York
$2.74M +$2.69M +99,500 New
Renaissance Technologies
34
Renaissance Technologies
New York
$2.7M +$2.64M +97,900 New
FAM
35
Fred Alger Management
New York
$2.56M +$2.5M +92,785 New
Morgan Stanley
36
Morgan Stanley
New York
$2.37M -$1.05M -39,036 -31%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$2.25M +$1.26M +46,653 +133%
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
$1.86M +$719K +26,622 +65%
Marshall Wace
39
Marshall Wace
United Kingdom
$1.26M +$1.23M +45,578 New
CSS
40
Cubist Systematic Strategies
Connecticut
$1.15M +$1.07M +39,682 +1,846%
CCM
41
Conway Capital Management
California
$889K -$270K -10,000 -24%
PPA
42
Parametric Portfolio Associates
Washington
$761K +$36.5K +1,351 +5%
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$731K +$361K +13,373 +102%
MFS
44
Mirabella Financial Services
United Kingdom
$714K +$700K +25,920 New
MWNA
45
Marshall Wace North America
New York
$701K +$687K +25,464 New
Bank of America
46
Bank of America
North Carolina
$698K +$582K +21,545 +573%
HS
47
HighVista Strategies
Massachusetts
$579K -$219K -8,123 -28%
JP Morgan Chase
48
JP Morgan Chase
New York
$483K -$2.42M -89,682 -84%
State of Wisconsin Investment Board
49
State of Wisconsin Investment Board
Wisconsin
$433K +$24.9K +922 +6%
Man Group
50
Man Group
United Kingdom
$400K +$391K +14,500 New

OLMA Hedge Fund Activity: Q3 2021 in Review

76 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q3 2021, worth a combined $1.01B — down 3.3% from $1.05B a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new OLMA positions and 9 closed out — a net gain of 8 holders — while 28 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $23.5M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $24.5M sold.

  • 76 institutional investors held Olema Pharmaceuticals (OLMA) as of Q3 2021, up from 69 in Q2 2021.
  • Funds reported $1.01B of Olema Pharmaceuticals stock for Q3 2021, down 3.3% quarter-over-quarter.
  • 17 funds opened new Olema Pharmaceuticals positions in Q3 2021 and 9 closed out, a net change of +8 holders.
  • The largest Olema Pharmaceuticals buyer in Q3 2021 was BlackRock, an estimated $23.5M added.
  • The largest Olema Pharmaceuticals seller in Q3 2021 was Avoro Capital Advisors, an estimated $24.5M sold.

Based on aggregated 13F filings for Q3 2021.